Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $226.92 billion. The enterprise value is $245.62 billion.
| Market Cap | 226.92B |
| Enterprise Value | 245.62B |
Important Dates
The next confirmed earnings date is Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | Mar 12, 2025 |
Share Statistics
Novartis AG has 1.98 billion shares outstanding. The number of shares has decreased by -2.72% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.98B |
| Shares Change (YoY) | -2.72% |
| Shares Change (QoQ) | -1.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.88B |
Valuation Ratios
The trailing PE ratio is 19.00 and the forward PE ratio is 13.82.
| PE Ratio | 19.00 |
| Forward PE | 13.82 |
| PS Ratio | 4.39 |
| Forward PS | 4.26 |
| PB Ratio | 5.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.96 |
| P/OCF Ratio | 12.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.89, with an EV/FCF ratio of 15.11.
| EV / Earnings | 20.57 |
| EV / Sales | 4.75 |
| EV / EBITDA | 11.89 |
| EV / EBIT | 15.05 |
| EV / FCF | 15.11 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.04 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.50 |
| Debt / FCF | 1.93 |
| Interest Coverage | 16.22 |
Financial Efficiency
Return on equity (ROE) is 26.28% and return on invested capital (ROIC) is 13.72%.
| Return on Equity (ROE) | 26.28% |
| Return on Assets (ROA) | 10.09% |
| Return on Invested Capital (ROIC) | 13.72% |
| Return on Capital Employed (ROCE) | 22.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, Novartis AG has paid $1.70 billion in taxes.
| Income Tax | 1.70B |
| Effective Tax Rate | 12.47% |
Stock Price Statistics
The stock price has increased by +12.60% in the last 52 weeks. The beta is 0.49, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +12.60% |
| 50-Day Moving Average | 103.88 |
| 200-Day Moving Average | 108.06 |
| Relative Strength Index (RSI) | 75.85 |
| Average Volume (20 Days) | 2,173,749 |
Short Selling Information
The latest short interest is 3.99 million, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 3.99M |
| Short Previous Month | 4.42M |
| Short % of Shares Out | 0.20% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.84 |
Income Statement
In the last 12 months, Novartis AG had revenue of $51.72 billion and earned $11.94 billion in profits. Earnings per share was $5.87.
| Revenue | 51.72B |
| Gross Profit | 38.91B |
| Operating Income | 16.32B |
| Pretax Income | n/a |
| Net Income | 11.94B |
| EBITDA | 20.66B |
| EBIT | 16.32B |
| Earnings Per Share (EPS) | $5.87 |
Balance Sheet
The company has $13.35 billion in cash and $31.40 billion in debt, giving a net cash position of -$18.05 billion or -$9.14 per share.
| Cash & Cash Equivalents | 13.35B |
| Total Debt | 31.40B |
| Net Cash | -18.05B |
| Net Cash Per Share | -$9.14 |
| Equity (Book Value) | 44.13B |
| Book Value Per Share | 22.30 |
| Working Capital | 1.01B |
Cash Flow
In the last 12 months, operating cash flow was $17.62 billion and capital expenditures -$1.37 billion, giving a free cash flow of $16.25 billion.
| Operating Cash Flow | 17.62B |
| Capital Expenditures | -1.37B |
| Free Cash Flow | 16.25B |
| FCF Per Share | $8.23 |
Margins
Gross margin is 75.22%, with operating and profit margins of 31.55% and 23.09%.
| Gross Margin | 75.22% |
| Operating Margin | 31.55% |
| Pretax Margin | 26.37% |
| Profit Margin | 23.09% |
| EBITDA Margin | 39.95% |
| EBIT Margin | 31.55% |
| FCF Margin | 31.42% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 2.84%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 2.84% |
| Dividend Growth (YoY) | -13.24% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 55.83% |
| Buyback Yield | 2.72% |
| Shareholder Yield | 5.56% |
| Earnings Yield | 5.26% |
| FCF Yield | 7.16% |
Analyst Forecast
The average price target for Novartis AG is $123.67, which is 7.01% higher than the current price. The consensus rating is "Hold".
| Price Target | $123.67 |
| Price Target Difference | 7.01% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 1.74% |
| EPS Growth Forecast (5Y) | 9.86% |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.92 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.92 |
| Piotroski F-Score | 6 |